First biosimilar of dornase alfa inhalation solution for CF approved in Russia, companies announce

Cystic Fibrosis News Today

19 September 2019 - A biosimilar of dornase alfa inhalation solution, with the same therapeutic activity as Pulmozyme, its reference therapy, was approved for use in Russia, Selexis and Generium Pharmaceutical announced.

A biosimilar is like a generic formulation of an approved biological treatment in that it is clinically similar to its reference medicine.

Named Tigerase, this is the first dornase alfa biosimilar made available anywhere in the world to treat people with cystic fibrosis (CF). “We believe patients will be able to maintain a higher quality of life on our dornase alfa inhalation solution,” Dmitriy Kudlay, MD, CEO of Generium, said in a press release.

Read Cystic Fibrosis News Today article 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Biosimilar , Russia